C=o Bonded Directly To The Hetero Ring (x Is Chalcogen) Patents (Class 514/448)
  • Patent number: 6248773
    Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-heteroarylalk(en)yl derivatives as ocular hypotensives.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: June 19, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Robert M. Burk
  • Publication number: 20010003780
    Abstract: Retinoid antagonist compounds have been found to be useful in the prevention and/or minimization of surgical adhesion formation.
    Type: Application
    Filed: December 8, 2000
    Publication date: June 14, 2001
    Inventors: Kenneth M. Tramposch, Xina Nair, Anne Marinier, Fred Christopher Zusi
  • Patent number: 6225336
    Abstract: This invention provides novel compounds which are dual antagonistic to TXA2 and PGD2 receptors and the pharmaceutical compositions containing them. They are useful for treating, for example, systemic mastocytosis and disorder of systemic mast cell activation as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, and inflammation. In detail, this invention provides a compound of the foumula (I): pharmaceutically acceptable salt thereof, or hydrate thereof.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: May 1, 2001
    Assignee: Shionogi & Co., Ltd.
    Inventor: Tsunetoshi Honma
  • Patent number: 6221838
    Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: April 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
  • Patent number: 6218426
    Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: April 17, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Mark Brian Anderson, Alexander Polinsky, Yufeng Hong, Vlad Edward Gregor
  • Patent number: 6214862
    Abstract: Compounds related to lactacystin and lactacystin &bgr;-lactone, pharmaceutical compositions containing the compounds, and methods of use.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: April 10, 2001
    Assignee: President and Fellows of Harvard College
    Inventors: Gabriel Fenteany, Timothy F. Jamison, Stuart L. Schreiber, Robert F. Standaert
  • Patent number: 6197789
    Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C═O or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H, R5 is I, O(C1-C4)alkyl or H and R6 is I, O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to elevate the level of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF-beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: March 6, 2001
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, James C. Metcalfe, Lawrence L. Kunz, Robert W. Schroff
  • Patent number: 6197817
    Abstract: Disclosed are compounds of the formula: R represents hydrogen or is a C-3 to C-6 cycloalkyl or C-4 to C-10 straight or branched carbon chain alkyl-cycloalkyl or a group —B—D, where B is C-2 to C-10 straight or branched carbon chain alkyl and D is hydroxy or alkyloxy or 2,3-dihydroxypropyl or 2,3-dialkyloxypropyl or 2,2-dialkyl-1,3-dioxolane-5-methyl, where alkyl is C-1 to C-10 straight or branched carbon chain; W represents CH(CH3)CH2—, C(CH3)2CH2—; Z represents hydrogen, —NHCOR2, —NHCONR2R3 or —NHSO2R2 or —NHSO2NR2R3 or —NHCOOR4 wherein R4 is alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, alkoxyaryl, cycloalkyl of from 3 to about 8 carbon atoms.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: March 6, 2001
    Assignee: Selectus Pharmaceuticals, Inc.
    Inventors: William L. Matier, Shyam Patil
  • Patent number: 6194443
    Abstract: The present invention pertains to new aminophenol derivatives of the following general formula (1), their preparation and their use as fungicides. wherein Y1, Y2, Y3, Y4, R1, and Z are as defined in the description.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: February 27, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Bernd-Wieland Krüger, Heinz-Wilhelm Dehne, Klaus Stenzel
  • Patent number: 6190695
    Abstract: This invention provides a pharmaceutical composition comprising a non-peptide osteogenesis-promoting substance and a polyethylene glycol or a derivative thereof, which can be advantageously used as a agent for preventing or treating various bone diseases (e.g., osteoporosis) in view of the high oral absorbability and stability of the active ingredient.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: February 20, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tetsuo Hoshino, Kazuhiro Saito, Susumu Iwasa
  • Patent number: 6166082
    Abstract: Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula(T).sub.x A--B--D--E--Gwherein A and B are aryl or heteroaryl rings; each T is a substituent group; x is 0, 1, or 2; the group D represents ##STR1## the group E represents a three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and the group G represents --M, ##STR2## in which M represents --CO.sub.2 H, --CON(R.sup.11).sub.2, or --CO.sub.2 R.sup.12 ; andR.sup.13 represents any of the side chains of the 19 noncyclic naturally occurring amino acids, and include pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: December 26, 2000
    Assignee: Bayer Corporation
    Inventors: Harold Clinton Eugene Kluender, Guenter Hans Heinz Herbert Benz, David Ross Brittelli, William Harrison Bullock, Kerry Jeanne Combs, Brian Richard Dixon, Stephan Schneider, Jill Elizabeth Wood, Michael Christopher VanZandt, Donald John Wolanin, Scott M. Wilhelm
  • Patent number: 6160018
    Abstract: A method of preventing or delaying the onset of symptoms of Alzheimer's Disease includes the step of administering to a patient in need of such treatment a composition having an effective Alzheimer's Disease prophylactic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.
    Type: Grant
    Filed: March 10, 1997
    Date of Patent: December 12, 2000
    Assignee: Loma Linda University Medical Center
    Inventors: William J. Wechter, John D. McCracken
  • Patent number: 6150397
    Abstract: The present invention relates to certain 5-aroylnaphthalene derivatives of formula (I): ##STR1## that are inhibitors of prostaglandin G/H synthase, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: November 21, 2000
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: David Mark Rotstein, Eric Brian Sjogren
  • Patent number: 6150413
    Abstract: Novel pharmaceutically/cosmetically-active triaromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: November 21, 2000
    Assignee: Centre International de Recherches Dermatologiques
    Inventors: Jean-Michel Bernardon, Philippe Nedoncelle
  • Patent number: 6143780
    Abstract: Compounds of the formula ##STR1## wherein A and X are independently oxygen or sulphur;R.sup.6 is H, halogen, alkyl, alkoxy, alkylthio, cyano, or nitro;Y is --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 S--, or --CH.sub.2 SO.sub.2 --;Q is a substituted or unsubstituted phenyl or aromatic heterocyclic group:useful for the inhibition of the replication of HIV-1, in vitro and in vivo.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: November 7, 2000
    Assignees: Uniroyal Chemical Company, Inc., Uniroyal Chemical Co./CIE.
    Inventors: Walter Gerhard Brouwer, Ewa Maria Osika
  • Patent number: 6143790
    Abstract: There is disclosed a novel amino glycol derivatives of L-N.sup.6 -(1-iminoethyl)lysine, pharmaceutical compositions containing these novel compounds, and to their use in therapy, in particular their use as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: November 7, 2000
    Assignee: G.D. Searle & Co.
    Inventors: E. Ann Hallinan, Foe S. Tjoeng, Kam F. Fok, Timothy J. Hagen, Mihaly V. Toth, Sofya Tsymbalov, Barnett S. Pitzele
  • Patent number: 6140315
    Abstract: A method of decreasing atherosclerosis and its complications, such as myocardial infarction, stroke and peripheral vascular disease, wherein the method involves administering to a human or an animal an amount of goserelin acetate sufficient to decrease atherosclerosis and its complications.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: October 31, 2000
    Inventors: Kenneth M. Weisman, Michael Goldberg
  • Patent number: 6121268
    Abstract: Compounds with fungicidal properties having formula I ##STR1## where m and n are 0 or 1 provided that m+n is 1; X is hydrogen, halo, (C.sub.1 -C.sub.4)alkyl, or (C.sub.1 -C.sub.4)alkoxy; R is an optionally-substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, or heterocyclic group; R.sub.1 and R.sub.2 are hydrogen, optionally-substituted alkyl, cycloalkyl, cyano, carboxy alkyl, or aryl; at least one of R.sub.1 and R.sub.2 is hydrogen; and R.sub.3 is alkyl or haloalkyl.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: September 19, 2000
    Assignee: Rohm and Haas Company
    Inventors: Ronald Ross, Ted Tsutomo Fujimoto, Edward Michael Szapacs, Steven Howard Shaber
  • Patent number: 6114375
    Abstract: Compounds with fungicidal properties are presented having the formula ##STR1## wherein m and n are 0 or 1; X is hydrogen, halo, (C.sub.1 -C.sub.4)alkyl or alkoxy; Z is (C.sub.1 -C.sub.12) alkyl or haloalkyl; R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently hydrogen, a halogen, lower alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, arylcycloalkyl, or heterocyclyl, optionally substituted with one or more halogen atoms.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: September 5, 2000
    Assignee: Rohm and Haas Company
    Inventors: Ronald Ross, Ted Tsutomo Fujimoto, Steven Howard Shaber
  • Patent number: 6103708
    Abstract: This invention provides compounds of Formula I having the structure: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, W, X, Y, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: August 15, 2000
    Assignee: American Home Products Corporation
    Inventors: Paul J. Dollings, Robert E. McDevitt, Folake O. Adebayo
  • Patent number: 6096781
    Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I: ##STR1##
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: August 1, 2000
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Patent number: 6090843
    Abstract: This invention provides novel benzothiophene compounds of the formula I: ##STR1## which are useful for the treatment of the various medical conditions associated with postmenopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus, and cervix. The present invention further relates to pharmaceutical formulations of compounds of formula I.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: July 18, 2000
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Jeffrey Alan Dodge
  • Patent number: 6083986
    Abstract: Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: July 4, 2000
    Assignees: ICAgen, Inc., Eli Lilly & Company
    Inventors: Neil Alexander Castle, Sean Patrick Hollinshead, Philip Floyd Hughes, Jose Serafin Mendoza, Joseph Wendell Wilson, George Salvatore Amato, Serge Beaudoin, Michael Gross, Grant McNaughton-Smith
  • Patent number: 6069175
    Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, induding humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.
    Type: Grant
    Filed: October 21, 1997
    Date of Patent: May 30, 2000
    Assignee: Pfizer Inc.
    Inventor: Robert J. Aiello
  • Patent number: 6069172
    Abstract: A new use of the enantiomer (R)-ketoprofen and of its salts with suitable organic and inorganic bases in the therapy of neutrophil-dependent diseases and phlogistic processes is described as well as pharmaceutical preparations containing such compounds and useful for oral, parenteral or topical administration.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: May 30, 2000
    Assignee: Dompe' SpA
    Inventors: Riccardo Bertini, Cinzia Bizzarri, Laura Brandolini, Gabriella Melillo, Gianfranco Caselli, Gaetano Clavenna
  • Patent number: 6057347
    Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: May 2, 2000
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6057342
    Abstract: The present application describes amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein one of D and D' may be C(.dbd.NH)NH.sub.2 and the other H, and J.sup.1 and J.sup.2 may be O or CH.sub.2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: May 2, 2000
    Assignee: Dupont Pharmaceutical Co.
    Inventors: John Matthew Fevig, Donald Joseph Phillip Pinto, Mimi Lifen Quan, Petrus Fredericus Wilhelmus Stouten
  • Patent number: 6051588
    Abstract: A compound comprising a non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO group, a pharmaceutical composition including the compounds and methods of treatment of pain and/or inflammation using the compounds and compositions are disclosed. Also disclosed is a composition comprising a non-steroidal antiinflammatory agent and a compound that donates, transfers or releases nitric oxide.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: April 18, 2000
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6046190
    Abstract: The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.
    Type: Grant
    Filed: January 24, 1996
    Date of Patent: April 4, 2000
    Assignee: G.D. Searle & Co.
    Inventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Deborah E. Bertenshaw, Robert M. Heintz
  • Patent number: 6046220
    Abstract: The invention relates to novel propynyl or dienyl biaromatic compounds which have the general formula (I) ##STR1## as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: April 4, 2000
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventor: Jean-Michel Bernardon
  • Patent number: 6046229
    Abstract: A compound of the formula:Ar.sub.1 --B--Ar.sub.2wherein Ar.sub.1 is unsubstituted or substituted phenyl, thienyl, furanyl, or pyrrolyl, in which each substituent of the substituted phenyl, substituted thienyl, substituted furanyl, and substituted pyrrolyl, independently, is aldehyde, acyl, ester, carboxyl, amido, nitrile, nitro, cyano, acetal, ketal, oxoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, iminoalkyl, acid halide, aminoalkylaminoalkyl, aminoalkylaminoalkylamino, hydroxyalkylaminoalkyl, or hydroxyalkylaminoalkylaminoalkyl; B is, --CH.dbd.CH--, or --C C--, in which R is H, alkyl, hydroxyl, alkoxy, ester, aldehyde, hydroxyalkyl, aminoalkyl, carboxyl, --CH(OR.sub.1).sub.2, or NR.sub.2 R.sub.3, where each R.sub.1, independently, is H, alkyl, or acyl; and each of R.sub.2 and R.sub.3, independently, is H, alkyl, hydroxyalkyl, or aminoalkyl; and Ar.sub.
    Type: Grant
    Filed: January 6, 1998
    Date of Patent: April 4, 2000
    Assignee: Industrial Technology Research Institute
    Inventors: Ching Te Chang, Yuh-Lin Yang
  • Patent number: 6034110
    Abstract: A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering a retinoid, such as an RXR-selective retinoid, e.g. the compound of the formula: ##STR1## and a PPAR.gamma. specific ligand and pharmaceutically acceptable salts and esters and amides thereof.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: March 7, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Sunil Nagpal, Roshantha A. Chandraratna
  • Patent number: 6028100
    Abstract: The present invention provides dihalopropene compounds of the general formula: ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.10 alkyl or the like; L is C(.dbd.O)NH or the like; R.sub.2, R.sub.3 and R.sub.4 are independently halogen or the like; R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen or the like; m is an integer of 0 to 4; n is an integer of 0 to 2; X is chlorine or the like; Y is oxygen or the like; and Z is oxygen or the like, which have excellent insecticidal activity so that they are satisfactorily effective for the control of noxious insects.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: February 22, 2000
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Sanshiro Matsuo, Taro Hirose, Keiichi Izumi, Masaya Suzuki, Noriyasu Sakamoto, Kazunori Tsushima, Shigeru Saito, Hirotaka Takano
  • Patent number: 6025395
    Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders so as to ameliorate the further progress of symptoms. The methods involve the administration of a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. According to indication, the present method can be applied to individuals who are currently asymptomatic but at risk of developing Alzheimer's disease, to individuals who have mild cognitive symptoms that may either denote an incipient prodrome of Alzheimer's disease or represent early symptoms (prodromal stage), or to individuals who have a clinical diagnosis of Alzheimer's disease.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: February 15, 2000
    Assignee: Duke University
    Inventors: John C. S. Breitner, Kathleen A. Welsh-Bohmer
  • Patent number: 6025384
    Abstract: Tetrahydrofurans, tetrahydrothiophenes, pyrrolidines and cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. It has been determined that 5-lipoxygenase activity, oral availability, and stability in vivo (for example, glucuronidation rate) can vary significantly among the optical isomers of the disclosed compounds.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: February 15, 2000
    Assignee: LeukoSite, Inc.
    Inventors: Xiong Cai, Aberra Fura, Changgeng Qian
  • Patent number: 6013664
    Abstract: Novel microbicidal compositions based on thiophene-2-carboxylic acid derivatives, some of which are known, of the formula in whichR.sup.1, R.sup.2 and n have the meanings given in the description, and the use of these substances for controlling undesired microorganisms.Novel thiophene-2-carboxylic acid derivatives of the formula ##STR1## in which R.sup.1, R.sup.2 and p have the meanings given in the description, and a process for the preparation of the substances of the formula (I-a).
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: January 11, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reiner Fischer, Norbert Lui, Stefan Dutzmann, Gerd Hanssler
  • Patent number: 6013836
    Abstract: This invention relates to N'-substituted-N,N'-disubstitutedhydrazines of formula I ##STR1## wherein X and X' are independently O, S, or NR; A' and B' are independently substituted or unsubstituted aryl or aromatic heterocycle; wherein F is alkyl, alkenyl, or aralkyl; and wherein E is a tertiary carbon containing organic radical having a total of at least four carbon and halogen atoms but not more than six halogen atoms, or a non-tertiary carbon containing non-haloalkyl organic or organometallic radical having at least five atoms other than hydrogen, oxygen and halogen which are useful as insecticides, compositions containing those compounds, methods of producing the compounds, and methods of their use. More particularly, the invention relates to insect growth regulating compounds and compositions, and methods of using such compounds and compositions. Compounds of the present invention are particularly suitable for controlling plant-destructive insects in crops of cultivated plants, ornamentals and forestry.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: January 11, 2000
    Assignee: Rohm and Haas Company
    Inventors: Adam Chi-Tung Hsu, Harold Ernest Aller, Dat Phat Le, Donald Wesley Hamp, Barry Weinstein, Raymond August Murphy
  • Patent number: 6004987
    Abstract: The present invention relates to the use of at least one ligand which is specific for RXR receptors, in the preparation of a pharmaceutical composition to be administered systemically and intended to increase the cellular proliferation and/or differentiation modulatory activity of a ligand for at least one receptor of the superfamily of steroidal/thyroidal receptors, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with the RXRs, which is applied topically.
    Type: Grant
    Filed: June 19, 1996
    Date of Patent: December 21, 1999
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventors: Michel Demarchez, Andre Jomard
  • Patent number: 6001885
    Abstract: The retinoids, in particular the anti-AP-1 retinoids, effectively inhibit the expression of VEGF, and thus are useful for the therapeutic treatment of disease states manifesting an overexpression of VEGF.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: December 14, 1999
    Assignee: Centre International de Recherches Dermatologiques
    Inventors: Barbara Vega, Serge Michel, Annie Ladoux, Christian Frelin
  • Patent number: 6001866
    Abstract: This invention provides a method for treating or preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor of Formula I: ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, nitro, halo, CN, OR.sup.6, NR.sup.6 R.sup.7, --CO.sub.2 R.sup.6, CONR.sup.6 R.sup.7, CH.sub.2 OR.sup.6, or CH.sub.2 NR.sup.6 R.sup.7, and R.sup.2 and R.sup.3, and R.sup.4 and R.sup.5, when attached to adjacent ring atoms, can be --(CH.sub.2).sub.3 or 4 --;in which R.sup.6 and R.sup.7 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl or benzyl, and when taken together with the nitrogen to which they are attached, R.sup.6 and R.sup.7 can complete a cyclic ring having from 3 to 7 carbon atoms; ##STR2## in which R.sup.8, R.sup.8', R.sup.9, and R.sup.9' independently are hydrogen or C.sub.1 -C.sub.6 alkyl, n is 0, 1, or 2, and Z.sup..crclbar.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: December 14, 1999
    Assignee: Warner-Lambert Company
    Inventors: Joseph A. Cornicelli, Bradley D. Tait, Bharat K. Trivedi
  • Patent number: 5993864
    Abstract: A novel chelate complex allows the formation of stable solutions of molecular chlorine dioxide. The chelate complexes are composed of the electron-deficient chlorine dioxide molecule, which can accept an electron, and a chelating agent, which can contribute its available electrons to the accepting orbital of the chlorine dioxide molecule. Both active and passive methods of releasing the chlorine dioxide from such chelates by competitive displacement with selected metal cations are presented. In this manner a stabilized solution of molecular chlorine dioxide can be stored until needed and the chlorine dioxide released at time of use for cleaning, disinfection or other uses.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: November 30, 1999
    Inventor: Robert D. Kross
  • Patent number: 5981592
    Abstract: A composition for use in preventing colorectal cancer and other neoplastic diseases, such as breast cancer, includes an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof in an amount effective to elicit a chemoprotective effect. The composition is substantially free of the S-enantiomer of the R-NSAID. Therapeutic use of the composition is accompanied by reduced adverse side effects. A method of treating cystic fibrosis likewise includes the step of administering to a patient in need of such treatment a composition having an effective cystic fibrosis therapeutic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: November 9, 1999
    Assignee: Loma Linda University Medical Center
    Inventors: William J. Wechter, John D. McCracken
  • Patent number: 5968910
    Abstract: A composition and method for the prevention or treatment of HIV-1 infection comprising an HIV-1 reverse transcriptase-inhibiting heterocyclyl carb(ox/thio)anilide compound, a second HIV-1 reverse transcriptase inhibitor compound which does not select for the same HIV-1 mutant strain or strains selected for by the heterocyclyl carb(ox/thio)anilide compound, and, optionally, a third HIV reverse transcriptase inhibitor compound.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: October 19, 1999
    Assignee: Jan M. R. Balzarini
    Inventor: Jan Maria Rene Balzarini
  • Patent number: 5965612
    Abstract: 4-Cyano-4-deformylsordaricin derivatives are antifungal agents useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: October 12, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Bruno Tse
  • Patent number: 5962508
    Abstract: A regimen for inducing/stimulating hair growth and/or retarding hair loss on an individual in need of such treatment, comprising administering thereto, advantageously topically and for such period of time as required to elicit the desired effect, an effective amount of at least one RXR-type retinoid receptor agonist preferably having the structural formula(I): ##STR1## in which Ar is one of the following radicals: ##STR2##
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: October 5, 1999
    Assignee: Societe L'Oreal S.A.
    Inventors: Nelly Billoni, Yann Mahe, Bruno Bernard
  • Patent number: 5942538
    Abstract: The present invention relates to benzamidoxime derivatives represented by the formula ?I!; ##STR1## wherein R.sup.1 is unsubstituted or substituted C.sub.1 -C.sub.4 alkyl, unsubstituted or substituted C.sub.2 -C.sub.4 alkenyl or unsubstituted or substituted C.sub.2 -C.sub.4 alkynyl, R.sup.2 is phenyl optionally having substituents or heterocycle optionally having substituents X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.1 -C.sub.4 alkylthio or the like, and r.sub.1 and r.sub.2 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl or the like, having excellent fungicidal activity and being useful as a fungicide for agricultural and horticultural use, and methods for preparation thereof.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: August 24, 1999
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Isamu Kasahara, Hirohito Ooka, Shinsuke Sano, Hiroyasu Hosokawa, Homare Yamanaka
  • Patent number: 5925651
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: July 20, 1999
    Assignee: Merck & Co., Inc.
    Inventor: John H. Hutchinson
  • Patent number: 5914351
    Abstract: Compounds of the formula ##STR1## wherein Q is a hydrazone derivative;R.sup.1 is hydrogen, halogen, alkyl or alkoxy;R.sup.2 is hydrogen, halogen, alkyl, alkoxy, alkenoxy, alkynyloxy, halomethyl, trifluoromethoxy, alkylthio, nitro or cyano; andR.sup.6 is a substituted carboxamide, carbothioamide, phosphonosoamide, or phosphonothioamide,useful as anti-HIV agents.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: June 22, 1999
    Assignees: Uniroyal Chemical Company, Inc., Uniroyal Chemical Co./CIE.
    Inventors: Walter Gerhard Brouwer, Ewa Maria Osika
  • Patent number: 5895789
    Abstract: A pharmaceutical composition for parenteral administration having anti-inflammatory and analgesic properties is disclosed which contain, as the active principle, alkylammonium salts of 2-arylpropionic acids.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: April 20, 1999
    Assignee: Dompe' SpA
    Inventors: Marco Gentile, Luigi Boltri, Gaetano Clavenna
  • Patent number: RE36419
    Abstract: The present invention provides novel methods for prevention or treatment of primary and recurring squamous cell carcinoma of the oral cavity or oropharynx comprising topical administration, to the oral cavity or oropharynx, of an effective amount of an NSAID, especially a composition administering from about 0.001% to about 0.2% ketorolac to the oral cavity, alone or as an adjunct to surgery and/or radiation therapy.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: November 30, 1999
    Assignee: The Procter & Gamble Company
    Inventor: Paul Francis Cavanaugh, Jr.